1. Home
  2. QTTB vs ADV Comparison

QTTB vs ADV Comparison

Compare QTTB & ADV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Q32 Bio Inc.

QTTB

Q32 Bio Inc.

N/A

Current Price

$8.46

Market Cap

450.1M

Sector

Health Care

ML Signal

N/A

Logo Advantage Solutions Inc.

ADV

Advantage Solutions Inc.

N/A

Current Price

$27.74

Market Cap

523.2M

ML Signal

N/A

Company Overview

Basic Information
Metric
QTTB
ADV
Founded
2015
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
450.1M
523.2M
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
QTTB
ADV
Price
$8.46
$27.74
Analyst Decision
Strong Buy
Buy
Analyst Count
5
2
Target Price
★ $42.25
$42.00
AVG Volume (30 Days)
★ 605.5K
39.9K
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 136.78
N/A
EPS
★ N/A
N/A
Revenue
$53,737,000.00
★ $3,542,642,000.00
Revenue This Year
N/A
$1.41
Revenue Next Year
$150.00
$1.27
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.91
$0.49
52 Week High
$23.57
$47.45

Technical Indicators

Market Signals
Indicator
QTTB
ADV
Relative Strength Index (RSI) 24.42 26.50
Support Level $5.12 $22.08
Resistance Level $16.85 $28.07
Average True Range (ATR) 0.68 1.66
MACD -0.13 -0.68
Stochastic Oscillator 5.86 0.32

Price Performance

Historical Comparison
QTTB
ADV

About QTTB Q32 Bio Inc.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).

About ADV Advantage Solutions Inc.

Advantage Solutions Inc provides outsourced sales, marketing, merchandising, sampling, and retailer support services to consumer packaged goods manufacturers and retailers across North America. Its services are designed to support distribution, retail execution, shopper engagement, and private brand development across both physical and digital commerce environments. The company serves various clients across grocery, mass, club, retail pharmacy, convenience, and other channels. It operates through three reportable segments: Branded Services, Experiential Services, and Retailer Services. The majority of the revenue is derived from the Experiential Services segment, which provides in-store and digital sampling programs, demonstrations, and experiential events for manufacturers and retailers.

Share on Social Networks: